Galectin Therapeutics Inc (GALT)
NASDAQ:GALT
Want to see GALT full AI Analyst Report?
GALT Stock Chart & Stats
$5.71
-$0.06(-5.00%)
At close: 4:00 PM EST
$5.71
-$0.06(-5.00%)
Day’s Range― - ―
52-Week Range$1.85 - $7.13
Previous CloseN/A
Volume135.57K
Average Volume (3M)341.94K
Market Cap
$186.05M
Enterprise Value$304.03M
Total Cash (Recent Filing)$14.11M
Total Debt (Recent Filing)$135.72M
Price to Earnings (P/E)―
Beta0.83
Next Earnings
Aug 17, 2026EPS Estimate
-0.09Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.41
Shares Outstanding65,856,895
10 Day Avg. Volume287,288
30 Day Avg. Volume341,945
Financial Highlights & Ratios
PEG Ratio0.23
Price to Book (P/B)-2.11
Price to Sales (P/S)0.00
P/FCF Ratio-11.13
Enterprise Value/Market Cap1.63
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-16.33
Forecast
1Y Price Target
$11.00Price Target Upside92.64% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.31
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Focused Therapeutic Target (galectin-3)Galectin-3 is a clear, specialized biological target tied to fibrosis, inflammation and oncology. Maintaining a concentrated pipeline around a differentiated mechanism creates a durable scientific edge if clinical proof is achieved, concentrating R&D and regulatory strategy on one high-value indication set.
Operating Losses And Cash Burn Have ImprovedMaterial reduction in operating losses and cash burn versus the prior year indicates improved cost discipline and operational efficiency. That reduces near-term financing needs, extends runway, and gives management more time to advance trials, making the firm's survival prospects less binary over the next several months.
Lean Organizational StructureA very small workforce implies a low fixed-cost base and potential for capital-efficient trial execution via CRO partnerships. For a clinical-stage biotech, a lean headcount can stretch limited cash, enable flexible outsourcing, and allow management to allocate preserved capital toward critical milestones.
Bears Say
Deeply Negative Shareholders' EquityA profoundly negative equity position coupled with substantial debt signals structural financial weakness. This leverage constrains strategic options, increases refinancing and covenant risk, and limits the company's ability to absorb trial setbacks or fund multiple development programs without dilutive financing.
No Recurring Revenue; Persistent LossesAbsence of product revenue leaves the company fully reliant on capital markets or partnerships to fund operations. Persistent large net losses mean the firm cannot self-sustain R&D spending, increasing execution risk and making long-term planning dependent on successful fundraising or milestone-linked collaborations.
Ongoing Heavy Cash Consumption And Financing RelianceAlthough burn improved, the company still consumes significant cash and historically depends on external financing. This recurrent need for capital introduces dilution and execution timing risk, and makes progress contingent on market access to funding or securing partnerships that provide non-dilutive resources.
Galectin Therapeutics News
GALT FAQ
What was Galectin Therapeutics Inc’s price range in the past 12 months?
Galectin Therapeutics Inc lowest stock price was $1.85 and its highest was $7.13 in the past 12 months.
What is Galectin Therapeutics Inc’s market cap?
Galectin Therapeutics Inc’s market cap is $186.05M.
When is Galectin Therapeutics Inc’s upcoming earnings report date?
Galectin Therapeutics Inc’s upcoming earnings report date is Aug 17, 2026 which is in 58 days.
How were Galectin Therapeutics Inc’s earnings last quarter?
Galectin Therapeutics Inc released its earnings results on May 15, 2026. The company reported -$0.08 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.08.
Is Galectin Therapeutics Inc overvalued?
According to Wall Street analysts Galectin Therapeutics Inc’s price is currently Undervalued.
Does Galectin Therapeutics Inc pay dividends?
Galectin Therapeutics Inc does not currently pay dividends.
What is Galectin Therapeutics Inc’s EPS estimate?
Galectin Therapeutics Inc’s EPS estimate is -0.09.
How many shares outstanding does Galectin Therapeutics Inc have?
Galectin Therapeutics Inc has 65,856,895 shares outstanding.
What happened to Galectin Therapeutics Inc’s price movement after its last earnings report?
Galectin Therapeutics Inc reported an EPS of -$0.08 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -7.66%.
Which hedge fund is a major shareholder of Galectin Therapeutics Inc?
Currently, no hedge funds are holding shares in GALT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Galectin Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$11.00 (92.64% Upside)
$11.00 (92.64% Upside)
Crowd Wisdom
Neutral
Last 7 Days ▲ 1.4%
Last 30 Days ▼ 1.7%
Last 30 Days ▼ 1.7%
Technicals
SMA
Positive
20 days / 200 days
Momentum
87.59%
12-Months-Change
Fundamentals
Return on Equity
21.05%
Trailing 12-Months
Asset Growth
65.40%
Trailing 12-Months
Company Description
Galectin Therapeutics Inc
Galectin Therapeutics Inc. is a biopharmaceutical company in the clinical development phase, dedicated to discovering and advancing new therapies for a spectrum of illnesses, including fibrotic disorders and various cancers. The company's flagship therapeutic agent is belapectin (GR-MD-02), an inhibitor of galectin-3, which is a complex polysaccharide polymer. This compound is currently undergoing Phase III clinical trials, assessing its effectiveness in treating liver scarring linked to fatty liver disease and non-alcoholic steatohepatitis (NASH) cirrhosis, alongside its potential for cancer treatment. Beyond belapectin, Galectin Therapeutics is progressing GM-CT-01 through preclinical stages for the management of cardiac and vascular fibrosis. The company is also actively exploring additional uses for belapectin in conditions like psoriasis, lung fibrosis, and kidney fibrosis. Furthermore, through Galectin Sciences, LLC – a joint venture established with SBH Sciences, Inc. – the firm is involved in researching and developing small organic molecules designed to block galectin-3, intended for oral administration. Established in 2000, the company was initially known as Pro-Pharmaceuticals, Inc. before officially changing its name to Galectin Therapeutics, Inc. in May 2011. Its corporate headquarters are located in Norcross, Georgia.
GALT Stock 12 Month Forecast
Average Price Target
$11.00
▲(92.64% Upside)
Technical Analysis
Omeros
―
Voyager Therapeutics
―
Tectonic Therapeutic
―
Jade Biosciences
―
Tenaya Therapeutics
―
Ownership Overview
26.04% Insiders
3.82% Mutual Funds
4.52% Other Institutional Investors
62.36% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---